CEO Executive AssistantGlobal medical affairs has evolved from a post-approval support function to a strategic driver of pharmaceutical value creation. Medical affairs teams generate the real-world evidence that supports market access, build the key opinion leader relationships that shape clinical practice, drive scientific exchange with the medical community, and design the medical education programs that advance appropriate use of pharmaceutical products.
For pharmaceutical CEOs, this evolution means that medical affairs deserves more strategic attention than it has historically received, while also requiring a clear delegation model that allows the function to operate with appropriate scientific independence and professional credibility.
This framework helps pharmaceutical CEOs position themselves appropriately in global medical affairs: strategically engaged but operationally removed, shaping the function’s direction without undermining its scientific integrity.
The Strategic Importance of Global Medical Affairs
Understanding why medical affairs deserves CEO-level strategic attention helps calibrate the delegation model appropriately.
Market access support. Payers increasingly require robust clinical and real-world evidence to support formulary decisions. Medical affairs teams that generate compelling evidence and communicate it effectively to payers are a direct competitive advantage.
Key opinion leader relationships. KOL relationships, built and maintained by medical science liaisons and medical affairs directors, shape how physicians understand and prescribe pharmaceutical products. These relationships must be genuine, scientifically grounded, and managed with careful attention to compliance.
Regulatory support. Medical affairs teams contribute to regulatory strategy through advisory committee preparation, label negotiations, and post-marketing study design. Their scientific expertise is essential at key regulatory moments.
Medical information and pharmacovigilance. Medical affairs functions often include medical information services and pharmacovigilance, which carry both patient safety and regulatory compliance implications.
Data generation strategy. Medical affairs teams design and manage investigator-initiated studies, registry programs, and real-world evidence studies that generate the post-approval evidence needed to support market access and appropriate use.
The CEO’s Role in Global Medical Affairs
The CEO’s engagement with global medical affairs is strategic rather than operational.
Setting the strategic direction for medical affairs. The CEO should define the role of medical affairs in the company’s overall strategy: how much investment the function receives, which therapeutic areas it prioritizes, and how medical and commercial objectives are balanced. These decisions require CEO authority.
Ensuring organizational independence. The CEO must protect medical affairs from inappropriate commercial influence. The scientific credibility of medical affairs depends on their independence, and any perception that medical affairs activities are commercially directed creates both compliance risk and reputational risk. The CEO must set the organizational tone that makes this independence genuine.
Medical affairs in major regulatory moments. When advisory committee meetings, major regulatory submissions, or significant label negotiations involve medical affairs, the CEO should be informed and may need to engage when strategic decisions are required.
Top-tier KOL relationships. A small number of the most scientifically influential KOLs have relationships with pharmaceutical CEOs that carry organizational significance beyond what medical affairs staff can manage. The CEO maintains these select relationships personally.
Delegating Medical Affairs Operations
A strong chief medical officer should own global medical affairs operations, with a medical affairs leadership team that manages each regional and therapeutic area function.
Chief Medical Officer. The CMO owns the medical affairs strategy: the MSL deployment model, evidence generation priorities, medical education programs, KOL engagement strategy, and medical affairs investment across regions and therapeutic areas.
Regional Medical Affairs Directors. Regional directors in the US, EU, and key emerging markets own the medical affairs activities in their regions: managing local MSL teams, building regional KOL networks, executing regional evidence generation programs, and adapting global medical affairs strategy to regional market needs.
Medical Science Liaisons. MSLs own the field-based KOL relationship management function: conducting scientific exchange meetings, providing medical information support to healthcare providers, gathering clinical and scientific insights from the field, and supporting investigator-initiated research.
Medical Education function. A medical education director or team should own the design and execution of medical education programs: congress symposia, medical education grants, speaker bureau programs (within compliance guidelines), and digital medical education content.
Real-world evidence and outcomes research. An outcomes research team should own the design and execution of real-world evidence studies: registry design, claims data analyses, electronic health record studies, and other evidence generation programs.
For guidance on the broader pharma CEO delegation framework, see our resource on pharma CEO guide.
Global Medical Affairs Governance
Managing a global medical affairs function requires governance structures that maintain consistency across regions while allowing appropriate local adaptation.
A global medical affairs leadership team, with representation from all major regions, should own the governance of global medical affairs activities: setting standards, reviewing evidence generation plans, approving major medical education programs, and ensuring compliance with global policies.
The CEO should receive periodic medical affairs governance updates through the CMO rather than managing governance directly. Significant governance decisions, including those with major resource implications or compliance risks, should be escalated to the CEO.
Medical Affairs Compliance
Pharmaceutical medical affairs activities are subject to extensive compliance regulations, including the OIG guidelines on pharmaceutical company interactions with healthcare professionals, FDA promotional regulations, state gift laws, and the PhRMA code. Managing compliance in medical affairs is a specialized function.
A medical affairs compliance function or the broader corporate compliance team should own medical affairs compliance: developing and maintaining medical affairs policies, training MSLs and medical education staff, reviewing planned activities for compliance issues, and investigating compliance concerns.
The CEO ensures that the organization invests adequately in medical affairs compliance infrastructure and sets the organizational tone that makes compliance a genuine value rather than a bureaucratic constraint. But the operational compliance management belongs with compliance professionals.
KOL Strategy and Delegation
The KOL engagement strategy is one of the most important and most sensitive medical affairs functions. Done well, KOL engagement builds genuine scientific relationships that advance medical knowledge and appropriate drug use. Done poorly, it creates compliance risk and damages scientific credibility.
The CMO should own the KOL engagement strategy: defining the target KOL landscape, setting the standards for MSL scientific exchange, establishing the compliance framework for KOL relationships, and managing the most significant advisory board relationships.
MSLs own the individual KOL relationships in their territories, conducting scientific exchange according to established protocols and reporting insights from KOL interactions through a structured insight collection system.
The CEO engages with a small number of the most influential KOLs personally, where CEO-level relationship investment is strategically important. These relationships should be managed with the same scientific integrity and compliance standards as all other KOL relationships.
Evidence Generation Strategy
Developing the evidence base that supports market access and appropriate use is one of medical affairs’ most important contributions. Evidence generation strategy decisions have significant resource implications and require careful scientific and commercial coordination.
The CMO, in collaboration with the chief commercial officer and regulatory leadership, should own evidence generation strategy: identifying evidence gaps, prioritizing research questions, designing studies to address those gaps, and selecting the research partners and methods needed to generate compelling evidence.
The CEO engages with evidence generation strategy at the portfolio level: ensuring that evidence generation investments are aligned with the company’s commercial strategy and regulatory needs, and making resource allocation decisions when evidence generation priorities compete for limited investment.
Medical Affairs and Launch Excellence
As pharmaceutical companies approach product launches, medical affairs plays an increasingly critical pre-launch role: preparing the medical community for the new therapy, generating the evidence base needed for early market access decisions, and building the KOL relationships that will shape early clinical adoption.
Pre-launch medical affairs planning should be owned by the medical affairs leadership team in close collaboration with commercial, regulatory, and market access leadership. The CEO should ensure that pre-launch medical affairs investments are adequate and that medical and commercial strategies are well-integrated, but should not be managing pre-launch medical affairs activities operationally.
For guidance on delegating the commercial dimensions of launch planning, see our resource on pharma product launch.
Measuring Medical Affairs Performance
Medical affairs performance measurement has historically been challenging because the function’s outputs are often indirect and long-term. But a well-designed measurement framework can give the CEO and board visibility into medical affairs effectiveness.
The CMO should provide the CEO and board with regular updates on medical affairs performance metrics including: MSL reach and frequency with target KOLs, KOL satisfaction with scientific exchange, evidence generation milestones, medical education program reach and quality, and insights from field medical activities that inform commercial and regulatory strategy.
According to Harvard Business Review, pharmaceutical companies that invest in medical affairs as a strategic function and establish clear boundaries between medical and commercial activities consistently achieve better market access outcomes and stronger clinical relationships than those that under-invest or allow medical-commercial boundaries to blur.
International Medical Affairs Coordination
Managing medical affairs across multiple countries and regulatory environments requires coordination structures that balance global consistency with local flexibility.
A global medical affairs leadership framework, including regional medical directors with genuine authority over regional activities, gives the organization the ability to respond to local market needs while maintaining global scientific standards and compliance frameworks.
The CEO should ensure that regional medical affairs leaders have adequate resources and authority to manage their markets effectively, while also ensuring that global governance structures maintain the scientific and compliance standards that protect the company’s reputation across markets.
The CEO’s Medical Affairs Partnership
The most effective CEO-medical affairs relationship is one where the CEO is a genuinely informed partner to the CMO: understanding medical affairs strategy and priorities, asking good questions about evidence generation plans and KOL engagement activities, holding medical affairs to high standards of scientific quality and compliance, and investing in the function’s resources and capabilities.
This partnership enables the CMO and medical affairs team to operate with the organizational support and strategic direction they need, while the CEO focuses on the highest-level strategic and external leadership activities that are the CEO’s unique contribution to organizational success.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.